Patent · US Active

Aggrecan binding immunoglobulins

US11603401B2 · kind B2 · utility

1Cited by

0References

13Claims

0Family size

Assignees

Ablynx N.V. · BE
Merck Patent GmbH · DE

Inventors

Soren Steffensen · Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, BE
Gerald Beste · Evergem, BE
Guy Hermans · Merelbeke, BE
Hans Gühring · Geisenheim, DE
Christoph H. Ladel · Darmstadt, DE
Lars Toleikis · Kleinniedesheim, DE

Key dates

Filing date	Jun 4, 2018
Grant date	Mar 14, 2023
Priority date	—
Expiry date	Jun 4, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.